Category: Uncategorized

STERIS PAYS $2.1 BILLION FOR XODUS: MEDTECH COMPETITION IS SHIFTING FROM “SELLING EQUIPMENT” TO OWNING MORE ECONOMICS IN EVERY PROCEDURE

13/10/2026 Published by HealthBiz

Key Development STERIS has agreed to acquire Xodus Medical for $2.1 billion, adding a fast-growing surgical-consumables portfolio to an operating-room... Read more

Tags: #M&A

REMIGROMIG HITS PHASE 2B/3 BUT EXPOSES A COMMERCIAL PROBLEM: IN DME, A “NEW MECHANISM” IS NO LONGER ENOUGH WITHOUT A NEW ADVANTAGE

13/10/2026 Published by HealthBiz

Key Development Merck's remigromig has met the primary endpoint in the pivotal Phase 2b/3 BRUNELLO trial, validating Wnt-pathway activation as... Read more

Category: Uncategorized

Tags: #Global Trends

BMS SCORES TWO PHASE 3 WINS: THE BIGGER STORY IS BUILDING NEW GROWTH ENGINES FOR THE POST-ELIQUIS, POST-OPDIVO ERA

13/10/2026 Published by HealthBiz

Key Development Bristol Myers Squibb has delivered two positive Phase 3 readouts on the same day, but the programs represent... Read more

Category: Uncategorized

Tags: #Global Trends

GSK PUTS MORE THAN $800 MILLION INTO PENNSYLVANIA: BIG PHARMA IS COMPRESSING THE DISTANCE FROM R&D TO COMMERCIAL MANUFACTURING

12/10/2026 Published by HealthBiz

Key Development GSK plans to invest more than $800 million to transform its Upper Merion, Pennsylvania campus into an integrated... Read more

Category: Uncategorized

Tags: #Global Trends

ASPEN AND BAM BUSA HEAD FOR IPOS: THE BIOTECH WINDOW IS REOPENING — BUT PUBLIC CAPITAL IS BUYING CLINICAL PROOF, NOT PLATFORM PROMISES

12/10/2026 Published by HealthBiz

Key Development Aspen Neuroscience and Bambusa Therapeutics both filed S-1 registration statements on October 9, 2026, adding to evidence that... Read more

Category: Uncategorized

Tags: #Global Trends

FDA APPROVES TEVA’S WELTRUZA: THE SCHIZOPHRENIA RACE IS SHIFTING FROM “NEW DRUGS” TO REDESIGNING HOW PATIENTS RECEIVE TREATMENT

12/10/2026 Published by HealthBiz

Key Development The FDA has approved WELTRUZA, Teva's once-monthly subcutaneous extended-release olanzapine for adults with schizophrenia. Its significance is not... Read more

Category: Uncategorized

Tags: #Global Trends

E-PRESCRIPTIONS ARE MORE THAN A PAPER REPLACEMENT: VIETNAM IS BUILDING A DATA RAIL FOR THE ENTIRE MEDICATION JOURNEY

12/10/2026 Published by HealthBiz

Key Development Vietnam's e-prescription rollout has moved beyond an optional digitization exercise. By 2026, electronic prescribing is required across the... Read more

Category: Uncategorized

Tags: #Vietnam

VIETNAM TARGETS 20% DOMESTIC PHARMA INPUTS BY 2030: THE BOTTLENECK IS NOT ONLY MAKING APIs — IT IS FINDING WHO WILL BUY THEM

12/10/2026 Published by HealthBiz

Key Development Vietnam has updated its pharmaceutical-chemicals strategy with a target to supply approximately 20% of domestic drug-manufacturing input demand... Read more

Category: Uncategorized

Tags: #Vietnam